US Patent Issued to Chong Kun Dang Pharmaceutical on Oct. 14 for "1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same" (South Korean Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,440,484, issued on Oct. 14, was assigned to Chong Kun Dang Pharmaceutical Corp. (South Korea).

"1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same" was invented by Chang Sik Lee (Gyeonggi-do, South Korea), Jung Taek Oh (Gyeonggi-do, South Korea), Hokeun Yun (Gyeonggi-do, South Korea), Hyeseung Song (Gyeonggi-do, South Korea) and Hyunjin Michael Kim (Gyeonggi-do, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceu...